Skip to main content

Drug Safety

      RT @RHEUMarampa: Did you know?
      Teratogens may take the form of:
      ✳️Drugs & chemicals
      ✳️Physical agents
      ✳ï¸
      2 years ago
      Did you know? Teratogens may take the form of: ✳️Drugs & chemicals ✳️Physical agents ✳️Infections ✳️Metabolic conditions #ACR22 @Rheumnow #MedTwitter https://t.co/GfHL28RYjm
      RT @DrCassySims: Early TNFi use and cardiovascular events in AS

      Abstract #0415 #ACR22 @RheumNow

      📍17.6k patients, 9
      Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE https://t.co/7bCkfk7EYY
      RT @EBRheum: I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence!

      Receiving less HCQ =
      2 years ago
      I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence! Receiving less HCQ = more damage and more CVD Observational, not clearly causal, but should make you wonder... Are we sure we should be shooting for <5mg/kg/day? #ACR22 @RheumNow #0982 https://t.co/SuAwSumgu1
      RT @uptoTate: In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe in
      In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
      RT @Yuz6Yusof: #ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed:

      Breakthrough
      #ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed: Breakthrough infection 30% mostly mild; Severe 4%; 1 death Poor outcomes predicted by comorbidities & low IgG Risk reduced by 50% with each vac dose OK for RTX if vaccinated @RheumNow https://t.co/xyJsukm1Rh
      A Year in Review
      RT @RHEUMarampa: How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎
      2 years ago
      How can we differentiate statin-assoc autoimmune necrotizing myopathy from toxic statin #myopathy?🔎 Remember this important slide👇 #ACR22 @Rheumnow #acrreview https://t.co/hKMJuGDJWt